Previous 10 | Next 10 |
2023-03-26 23:52:00 ET Summary Highlightll Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. F-star, a Cambridge, UK biopharma, out-licensed global rights for a novel next-gen immuno-o...
2023-03-23 16:39:31 ET Biohaven press release ( NYSE: BHVN ): Q4 Non-GAAP EPS of -$1.27 beats by $0.01 . Cash, cash equivalents and marketable securities as of December 31, 2022 was $465.3 million, excluding $37.7 million of restricted cash, compared to $76.1 million a...
Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments PR Newswire Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global (ex- ...
2023-03-22 08:20:08 ET Biohaven ( NYSE: BHVN ) said it acquired global rights, excluding China regions, for BHV-8000 to treat brain disorders from Hangzhou Highlightll Pharmaceutical. Highlightll will get $10M cash upfront and $10M in Biohaven equity, dev...
Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders PR Newswire Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity fo...
Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting PR Newswire BHV-7000 differs pharmacologically and structurally from other known Kv7 compounds in development BHV-7000 demonstrates potent anti-seizure activit...
2023-03-09 17:06:21 ET Summary Biohaven is on the far side of its spin cycle and faces the world as a much diminished company. Biohaven has upcoming catalysts, but they are either early stage or have serious question marks. Biohaven has gotten ahead of itself and is overpriced...
Summary Soros' 13F portfolio value increased from $5.86B to $7.26B this quarter. The number of positions decreased from 270 to 208. Soros increased Alphabet and Tesla while decreasing Rivian, Amazon, Nike, T-Mobile, and Biohaven. Horizon Therapeutics at 4.48% of the portfolio is the...
Summary This is not an immediate call to start buying technology willy nilly. Or is this a tech only announcement. I'm merely projecting that selling pressure will likely reach a crescendo once the Fed raises rates again. Put together a shopping list. You have time to understand the...
The U.S. Food and Drug Administration (FDA) granted fast track designation to Biohaven ( NYSE: BHVN ) medicine taldefgrobep alfa to treat spinal muscular atrophy (SMA). SMA is an inherited motor neuron disorder characterized by loss of nerve cells leading to muscle weakness over time....
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
2024-05-29 12:00:07 ET Brian Skorney from Robert W. Baird issued a price target of $58.00 for BHVN on 2024-05-29 09:57:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $30.31. The overall price target consensus is at $...
2024-05-29 11:00:21 ET Leonid Timashev from RBC Capital issued a price target of $59.00 for BHVN on 2024-05-29 09:14:00. The adjusted price target was set to $59.00. At the time of the announcement, BHVN was trading at $28.69. The overall price target consensus is at $23...